Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: btd who wrote (220)	1/17/1998 12:37:00 AM
From: John Dwyer	Read Replies (2) \| Respond to of 1494

Good news on the Memantine trial will almost certainly boost the stock price over $1. However, they are also in violation because they failed to meet the tangible asset requirements. So these extensions are meaningless unless they get an infusion of cash, right? I expected NTII to partner if results were good but this suggests that they have some kind of deal close. Either a partner for Memantine or perhaps they are out-licensing Dynorphine. They must be telling NASDAQ something good... John